AUTHOR=Iula Rossella , De Novellis Danilo , Trastulli Fabio , Della Pepa Roberta , Fontana Raffaele , Carobene Angela , Di Perna Maria , D’Ambrosio Alessandro , Romano Martina , Leone Aldo , De Fazio Laura , Fiumarella Alfonso , Gaeta Giuseppe , Marafioti Violetta , Barbato Serafina , Palmieri Salvatore , Rocco Stefano , Serio Bianca , Califano Catello , Pane Fabrizio , Ferrara Felicetto , Giudice Valentina , Selleri Carmine , Catalano Lucio TITLE=Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience JOURNAL=Frontiers in Oncology VOLUME=12 YEAR=2022 URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.1026251 DOI=10.3389/fonc.2022.1026251 ISSN=2234-943X ABSTRACT=

Belantamab-mafodotin is an innovative and selective treatment for multi-refractory/relapsed multiple myeloma (MM) patients; however, available real-life experiences on efficacy and safety are limited. In this real-world multicentric retrospective study, we enrolled 28 MM patients treated in four Hematology units of Campania region, Italy, who received a median of six treatment lines prior to belantamab-mafodotin. The overall response rate (ORR) was 40% (complete remission, CR, 11%; very good partial remission, VGPR, 11%; and partial remission, PR, 18%), with a median progression-free survival (PFS) and overall survival (OS) of 3 and 8 months, respectively. One of the most frequent drug-related adverse events was keratopathy observed in nine (32%) patients, leading to therapy discontinuation in only three (11%) of them. Moreover, 22 out of 28 total patients who were treated with at least two administrations achieved an ORR of 50% (CR, 14%; VGPR, 14%; and PR, 22%) with a median PFS and OS of 5 and 11 months, respectively. In conclusion, our multicentric study confirmed efficacy and safety of belantamab-mafodotin in triple-refractory MM patients even in the real-life setting.